Skip to content
‹ Back to IndustriesSciences

Who Will be the Winners of Aerospace This Year?

There is a lot happening—and a lot getting ready to happen—in aerospace right now. Just last year, we saw five significant achievements in aerospace—but the two that will likely continue to be important in 2019 are AI-drive “generative design” and industrial 3-D printing. Artificial intelligence (AI) is likely going to continue to be a major…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Troy Camplin · · 3d PrintingAerospaceBezosBranson
Share
Who Will be the Winners of Aerospace This Year?

Key takeaways

01

There is a lot happening—and a lot getting ready to happen—in aerospace right now.

02

Just last year, we saw five significant achievements in aerospace—but the two that will likely continue to be important in 2019 are AI-drive “generative design” and industrial 3-D printing.

03

Artificial intelligence (AI) is likely going to continue to be a major…

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

There is a lot happening—and a lot getting ready to happen—in aerospace right now. Just last year, we saw five significant achievements in aerospace—but the two that will likely continue to be important in 2019 are AI-drive “generative design” and industrial 3-D printing.

Artificial intelligence (AI) is likely going to continue to be a major driver in a large number of industries, including all areas of design, and especially in aerospace design. Stronger yet lighter designs are the key to aerospace, and there is nothing that can drive both of these trends simultaneously like generative design. It is likely this will become especially important as the “space” part of “aerospace” moves more to the forefront.

Industrial 3-D printing will allow engineers to produce many of the parts designed through generative design—as well, of course, from standard design practices. This will save a great deal of time while also reducing waste. It will also allow for a great deal of manufacturing in space—it would certainly be more space-efficient to pack up printing materials and then print structures on site.

On Oct. 24, 2003, the Concorde landed for the very last time—ending supersonic passenger service. Yet, in 2019, Denver-based startup ‘Boom’ is planning to test-fly its own supersonic passenger jet, Overture. The fact that it has raised $100 million to bring its total funding to $141 million is certainly a sign that there are those who believe in its goal of making trans-Atlantic day trips—and flights from Los Angeles to Sydney, Australia in under seven hours—a possibility. While Boom is aiming for 2020 to get commercial flights underway, perhaps the 2019 test flights will get people thinking about bigger possibilities.

Among those bigger possibilities is the real possibility of the first commercial space trip in 2019. This is Richard Branson’s goal, and the successful flight of Virgin’s SpaceShipTwo right into the edge of space is what makes it truly possible. Jeff Bezos also plans to try to send someone into space in 2019 with his Blue Origin.

Indeed, the billionaire space race is likely to continue to mark milestone after milestone. It has already resulted in technological innovations not yet achieved by the military aerospace industry with SpaceX’s rocket re-landing, and the technological innovations are likely to continue throughout the next year.

Each of these elements will likely be able to feed into the others, driving even more innovation. Space planes need supersonic technology as much as does Boom’s Overture, and supersonic planes and space planes will need stronger, lighter components made possible by generative design and 3-D printing. Lighter, stronger, faster, cheaper—these are all results of the aerospace trends in 2019.

For the latest news, videos, and podcasts in the Science Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – twitter.com/ScienceMKSL

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

TC
Troy Camplin
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Antibody developability checks are moving into discovery instead of waiting for development

Antibody developability checks are moving into discovery instead of waiting for development

Maria Gonzalez-Pajuelo of FairJourney Bio says the order in antibody discovery is changing: developability has become a much more important consideration during discovery, rather than an issue left until later-stage development. The goal, she says, is that what comes out of discovery is something CMC can take forward easily.

  • 01Discovery-stage developability screens can rank many antibodies tested once or twice and may reduce surprises later in development, while development still focuses on several lots of a single antibody and answers different questions.

Oct 1, 2026

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

ISPE’s 2026 Annual Meeting and Expo in Washington, DC organizes its program around five tracks running from discovery to governance, with international program committee chair Connie Langer of Pfizer Global Supply and executive chair Jose Caraballo of JCO Global Advisory LLC describing how the tracks connect—and why AI is treated as a cross-cutting topic rather than a standalone track. Deloitte’s December 2025 survey of 280 executives frames the mood the program is built for.

  • 01ISPE’s 2026 Annual Meeting has no dedicated AI track; executive chair Jose Caraballo expects AI presentations across all five tracks, from discovery to governance.
  • 02Deloitte’s December 2025 survey of 280 biopharma and medtech C-suite executives found more than 75% confident in their own outlook but only 41% optimistic about the global economy, a mood the story says the ISPE chairs are programming for.
  • 03A staffing firm reports life sciences job openings falling even as digital fluency becomes a required skill, so the upskilling burden lands on the people already employed, which is where the mandatory, university-partnered AI training Connie Langer describes at her company sits.

Sep 30, 2026

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site designs preclinical tumor models to match specific therapies and delivery routes, rather than forcing treatments into standard study designs. It combines custom surgical procedures, cell line-derived xenografts, patient-derived xenografts (including post-treatment models), and biomarker capabilities to generate translational data that can help sponsors decide whether to advance a program.

  • 01Orthotopic brain tumor implantation using tagged models lets researchers track tumor growth in the original organ, aligning the model and delivery route with how therapies are intended to be tested.
  • 02Patient-derived xenografts developed from tumors after prior treatment may better reflect progressed disease, helping teams study therapies aimed at patients whose cancer has advanced after earlier treatment.
  • 03Combining biomarker analysis of preclinical model samples with clinical sample testing at one site could make it easier to connect what is measured in animals with what is later measured in patients.

Sep 30, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

TC
Troy Camplin

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512